Westpac Banking Corp’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $531K | Sell |
4,228
-56
| -1% | -$7.04K | 0.04% | 256 |
|
|
2025
Q1 | $474K | Sell |
4,284
-9,705
| -69% | -$1.07M | 0.03% | 261 |
|
|
2024
Q4 | $1.91M | Buy |
13,989
+1,429
| +11% | +$195K | 0.13% | 163 |
|
|
2024
Q3 | $1.45M | Buy |
12,560
+6,170
| +97% | +$711K | 0.1% | 194 |
|
|
2024
Q2 | $880K | Sell |
6,390
-396
| -6% | -$54.5K | 0.07% | 209 |
|
|
2024
Q1 | $936K | Hold |
6,786
| – | – | 0.07% | 210 |
|
|
2023
Q4 | $894K | Buy |
6,786
+4,805
| +243% | +$633K | 0.07% | 204 |
|
|
2023
Q3 | $223K | Sell |
1,981
-287
| -13% | -$32.3K | 0.02% | 369 |
|
|
2023
Q2 | $214K | Sell |
2,268
-4,828
| -68% | -$455K | 0.02% | 362 |
|
|
2023
Q1 | $718K | Hold |
7,096
| – | – | 0.01% | 702 |
|
|
2022
Q4 | $848K | Hold |
7,096
| – | – | 0.01% | 640 |
|
|
2022
Q3 | $754K | Hold |
7,096
| – | – | 0.01% | 667 |
|
|
2022
Q2 | $692K | Hold |
7,096
| – | – | 0.01% | 718 |
|
|
2022
Q1 | $665K | Hold |
7,096
| – | – | 0.01% | 748 |
|
|
2021
Q4 | $604K | Hold |
7,096
| – | – | 0.01% | 768 |
|
|
2021
Q3 | $681K | Hold |
7,096
| – | – | 0.01% | 772 |
|
|
2021
Q2 | $691K | Hold |
7,096
| – | – | 0.01% | 795 |
|
|
2021
Q1 | $690K | Hold |
7,096
| – | – | 0.01% | 745 |
|
|
2020
Q4 | $680K | Hold |
7,096
| – | – | 0.01% | 788 |
|
|
2020
Q3 | $682K | Hold |
7,096
| – | – | 0.01% | 747 |
|
|
2020
Q2 | $866K | Hold |
7,096
| – | – | 0.01% | 673 |
|
|
2020
Q1 | $614K | Hold |
7,096
| – | – | 0.01% | 690 |
|
|
2019
Q4 | $763K | Buy |
+7,096
| New | +$763K | 0.01% | 741 |
|